Stockscreener 앱 받기
15.26
13.04%
1.76
시간 외 거래:
15.33
0.07
+0.46%
Erasca Inc 주식(ERAS)의 최신 뉴스
Guggenheim more than doubles Erasca (ERAS) PT following clinical progress and updated pipeline models - MSN
TNGX stock hits record high on inking collaboration deal with ERAS - MSN
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (ONC), Argenx Se (ARGX) and Erasca (ERAS) - The Globe and Mail
Erasca Inc stock hits 52-week high at $14.63 - Investing.com Nigeria
Chipmakers Recap: Should I invest in Erasca Inc before earnings2026 Valuation Update & Weekly Sector Rotation Insights - baoquankhu1.vn
Erasca Form 144: Foundation Lists Proposed Common Sales | ERAS SEC FilingForm 144 - Stock Titan
Erasca’s Stock Faces Pressure as CMO Offloads Shares - StocksToTrade
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts - AOL.com
Erasca’s CMO Stock Sale Raises Eyebrows Amid Market Uncertainty - timothysykes.com
FTAI Aviation To Rally More Than 43%? Here Are 10 Top Analyst Forecasts For Friday - Sahm
Assessing Tango Therapeutics (TNGX) Valuation After Vopimetostat Progress And New Erasca Collaboration - simplywall.st
Erasca secures worldwide rights to RAS-targeting drug ERAS-0015 By Investing.com - Investing.com Nigeria
Erasca’s Chief Medical Officer Divests Shares Amid Strategic Uncertainties - StocksToTrade
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), MindWalk Holdings (HYFT) and Erasca (ERAS) - The Globe and Mail
Erasca stock price target raised to $20 by H.C. Wainwright on trial data - Investing.com Nigeria
Stifel reiterates Buy rating on Erasca stock, $20 target By Investing.com - Investing.com Canada
Stifel reiterates Buy rating on Erasca stock, $20 target - Investing.com
Decoding Erasca Inc (ERAS): A Strategic SWOT Insight - GuruFocus
Erasca, Inc. 2025 Annual Report: Erasing Cancer with Modality-Agnostic RAS/MAPK Pathway Therapeutics and Innovative Precision Oncology Strategies - Minichart
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results - The Manila Times
Erasca 10-K: Net loss $124.55M; cash and securities $341.8M - TradingView
Erasca, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Erasca (NASDAQ: ERAS) narrows 2025 loss and funds runway into H2 2028 - Stock Titan
Cancer-drug maker Erasca raises $259M, says cash lasts to 2028 - Stock Titan
A Look At Erasca (ERAS) Valuation After Securing Global Rights To ERAS-0015 - simplywall.st
Erasca (ERAS) to Release Earnings on Thursday - MarketBeat
Stifel raises Erasca stock price target to $20 on China expansion - Investing.com India
Erasca secures worldwide rights to RAS-targeting drug ERAS-0015 - Investing.com India
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau - Bitget
Global cancer drug rights: Erasca takes ERAS-0015 worldwide - Stock Titan
Erasca (NASDAQ:ERAS) Hits New 52-Week HighTime to Buy? - MarketBeat
Guggenheim Maintains Erasca (ERAS) Buy Recommendation - MSN
Erasca (ERAS) And Tango Target MTAP-Deleted Cancers With Dual Inhibition Strategy – What Changes? - simplywall.st
Growth Recap: How interest rate cuts could boost Erasca Inc. stock2025 Technical Overview & Community Verified Watchlist Alerts - Naître et grandir
TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS - The Globe and Mail
Tango Therapeutics Stock Jumps 36% to a New High. Here’s What’s Driving the Move - TIKR.com
Erasca’s chief medical officer Morris sells $300k in ERAS stock - Investing.com Australia
Erasca’s chief medical officer Morris sells $300k in ERAS stock By Investing.com - Investing.com India
Erasca Insider Sold Shares Worth $300,760, According to a Recent SEC Filing - marketscreener.com
Erasca (ERAS) CMO exercises options, sells 20,000 shares under 10b5-1 plan - Stock Titan
Erasca (ERAS) Sees Target Price Raised By Clear Street To $20 | - GuruFocus
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights - Sahm
Tango Therapeutics rallies after oncology drug collaboration with Erasca - Mugglehead Investment Magazine
Clear Street raises Erasca stock price target on combination trial deal - Investing.com India
Clear Street raises Erasca stock price target on combination trial deal By Investing.com - Investing.com South Africa
1.20%
0.06%
자본화:
|
볼륨(24시간):